DOCSLIB.ORG

8252644.45 in 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
8252644.45 in 2004 Detail Expenditures by Sponsor Federal Name FY04 Expenditures National Cancer Institute 37,657,271.58 Heart,Lung & Blood 36,598,255.95 NIMH 27,996,752.16 Gen Med Sciences 27,396,844.18 Child Health & Hum Dev 27,094,951.12 Allergy & Infect Dis 22,974,536.45 NSF 22,491,966.99 Department of Education 22,092,520.94 AID 18,132,198.51 Diab & Dig Kid Dis 16,391,741.95 Ctr for Disease Cntrl (CDC) 14,342,287.82 National Center for Res Resr 10,974,299.16 Envir Health Sciences 9,718,945.61 Neuro/Disorder/Strok 9,425,134.97 EPA 8,252,644.45 National Institute Dntl & Crani 7,231,676.14 Alcohol Abuse & Alco 6,410,943.85 National Institute Nursing Res 5,180,742.47 National Institute Drug Abuse 4,950,725.37 Arth Musculosk Skin 3,928,512.33 National Institute Biomed Imag 3,717,437.09 Bureau of Health Prof 3,381,842.62 NASA 2,859,647.59 Health Resour Ser Admi (HRSA) 2,820,908.52 SBA 2,473,842.30 Fogarty Internat Center 2,452,873.44 National Institute on Aging 2,403,798.32 US Army Med Res 2,251,058.09 Department of Energy 2,192,409.70 US Department Transportation 2,174,996.91 Deaf&Other Cmnca Dis 2,045,222.90 Office of Naval Research 1,871,758.62 Agcy Hth Care Research 1,561,952.45 Maternal & Chld Health 1,394,120.99 National Institute Dental Res 1,358,816.75 National Eye Institute 1,273,119.53 National Center Com & Alt Me 1,171,914.53 Agcy Healthcare Res Qu 932,958.57 Women's Health Initiat 909,921.28 National Library of Med 794,130.01 National Center on Child Abu 761,335.37 Office Rural Hth Policy 754,994.20 Child Care Bureau 731,849.20 National Center Human Genome 680,518.08 National Center Minor Health 674,859.34 National Human Genome Res 667,800.29 USAF-Office of Sci Res 645,719.44 US Department Agriculture 621,531.08 US Army Research Office 569,236.57 Admin on Dev Dis 561,274.96 HRSA Div of Medicine 544,198.16 Head Start Bureau 534,255.06 Div of Medicine-Bhp 491,313.95 Children's Bureau 359,736.10 US Department Commerce 342,530.21 US Department Defense 325,418.45 1 of 22 OSR FY04 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY04 Expenditures Federal (continued) Indian Health Servic 225,084.75 US Department Interior 187,233.22 Medicare Paymnt Advi 172,537.62 NEH 148,292.17 National Center Research Resour 122,589.56 Corp for National Service 121,431.75 Uniformed Serv Univ 115,420.75 Naval Air Warfare 114,799.00 Office of Secretary 107,729.01 US Department of State 106,232.39 Hiv/Aids Bureau 81,236.73 National Institute Gen Med Sc 79,826.20 FDA 78,171.70 National Archives 74,443.02 NEA 63,794.94 Department of Hud 61,262.79 Department of Veterans Aff 58,969.05 Center Medicre & Medicd 58,968.35 Institute Museum Services 57,160.95 Institute Museum & Librar 53,040.47 National Security Agncy 35,415.38 National Acad of Science 35,149.28 Sub Abuse/Mentl Health 34,585.65 US Geological Su/Doi 34,202.26 Naval Health Research Center 34,120.96 National Park Service 29,175.70 US Department of Justice 25,989.01 US Peace Corps 19,232.59 Institute Envir Health Sci 18,233.51 FEMA 14,502.78 National Hist Publicatio 8,432.60 US Department of The Army 5,158.15 US Department Army - Darpa 925.30 Div Acquisition Mgmt 311.14 US Air Force -1,479.05 Federal Subtotal 390,934,432.35 Indirect Federal 6671P Foundation 35,029.42 Academyhealth 129,003.63 Alan Penn & Assoc 55,035.26 Albany Med College 16,790.87 Albert Einstein Coll 10,335.41 Amer Coll Radiology 573,423.52 Amer College Ob-Gyn -2,119.08 American Cancer Society 7,675.00 American Egg Board 67,072.01 Argonne National Labs 3,276.30 Arizona State University 566.68 Artecel Sciences, In -15.30 Assc Amer Medical 270,566.61 Assc Teachrs Prev Md 349,564.94 Assoc Amer Med Colle 36,856.49 Assoc Liaison Office 2,837.91 Assoc Sch Pub Health 3,986,567.23 Atlanta Research Edu Foundation 63,320.53 2 of 22 OSR FY04 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY04 Expenditures Indirect Federal (continued) Awwa Research Foundation 626,333.30 Axio Research Corp 34,657.08 B Thompson Ins Plant 108,208.07 Barnes-Jewish Hosp 10,503.62 Battellle, Inc 60,136.46 Baylor Col Med 4,782.86 Bellomo-Mcgee, Inc 13,138.99 Bioreliance Corp 16,603.64 Boston University 292,135.87 Brandies University 6,171.32 Brown University 229,896.32 Calgb/University Chicago 5,209.64 California Institute Tech 264,203.28 Cancervax 36,118.79 Center Line Prod 137,820.61 Ch2M Hill 118,897.77 Chatham Research 147,742.85 Children's Hosp Phil 39,977.67 Children's Hosp/Bost 45,695.36 Chldren Hosp Oakland 31,552.76 Chldrns Hosp Reg Med 26,293.43 Chldrns Hosp Research Center 27,945.88 Clemson University 103,522.03 Coda, Inc 100,322.54 Columbia Hosp/Chmcd 762.93 Columbia University 28,609.24 Courtesy Assoc 51,446.43 Darpharma, Inc 11,300.53 Dartmouth College 261,985.47 DC Department Hmn Ser-Oecd 144,330.31 Debby Cryer & Assoc 20,397.11 Duke Clinical Research 20,057.55 Duke University 4,219,041.76 Duke University Med Center 1,596,282.26 Dynamac Corporation -5,202.04 E Glaser Ped Aids Foundation 60,901.02 E H Pechan & Assoc 50,879.52 Eastern Virginia Med Sch 34,620.98 Emory University 137,554.60 Encelle, Inc 6,950.28 Engenderhealth, Inc 38,573.51 Environmental Export -37.01 Family Health Intnl 200,670.04 Family Violence & Ra 38,624.80 Flying Bridge Techno 104,527.98 Foundation Children's Oncol 4,008.41 Geo-Centers, Inc 168,939.98 Georgia Institute of Tech 240,719.98 Georgia State University 79,033.52 Gynecologic Oncology 87,669.46 Harvard University 77,050.04 Health Sys Res, Inc 93,697.12 Health Sys Research Inc 84,368.36 Henry Ford Health Sys 27,398.36 Hosp Joint Diseases 29,583.57 Hosp Special Surgery 74,349.87 3 of 22 OSR FY04 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY04 Expenditures Indirect Federal (continued) IBM Business Consult 10,313.90 Icf Consulting 147,797.98 Icf Inc 25,910.98 Indiana University 152,328.65 Inotek Corporation 4,393.06 Institute Ecosystem Studi 49,620.09 Intellitools Inc 8,279.19 Intrahealth 20,834.94 Iowa State University 123,845.37 IT Corporation 52,269.00 Jackson State University 349,257.20 Jaeb Center for Health Re 23,636.84 Jhpiego Corp 1,026.28 Johns Hopkins University 3,843,066.30 Joint Oceangphc Institute 2,052.26 Kaiser Foundation Res Institute 9,598.00 Karolinska Institute 63,646.82 Kenan Institute Asia 268,267.42 Lambada Technologies 37,464.51 Lehigh University -4.88 MA Institute of Technology 173,967.88 Madison Tech Internl 8,070.00 Management Sciences -7,687.65 Marine Biological La 21,913.39 Marshfield Clinic Foundation 11,425.04 Maryland Med Res Institute 8,261.17 Mclean Hospital 1,416.34 Mcnc 602,499.33 Med Unv of Sc 139,081.89 Medical College Ohio 40,764.62 Mfm Group, Inc 13,723.55 Michigan St University 135,221.03 Mi-Corporation 8,287.33 Miriam Hospital 10,912.50 Mississippi State Un 14,224.39 Mt Sinai Sch of Med 151,844.62 Naccho 3,737.11 National Acad of Science 337,177.66 National Assoc St Ems 56,592.76 National Brd Profes Teach 136,469.17 National Chldhd Cncr Foundation 45,694.29 National Init Chld Healthcr 52,043.16 National Jewish Med Research 143,273.68 National Rnl Enrg Lab/Mri 221,417.50 National Safety Council 40,710.34 Natural Pharmacia In 10,318.39 Neighbrhd Reinv Corp 38.29 New Eng Med Center Hos 16,180.90 New England Med Hosp 28,808.77 New Hanover Reg Med 180.68 New Mexico Tech 3,506.63 New York University 23,343.64 Northern Calif Institute 55.48 Northwestern University 62,043.46 Nova Southeast University 189,961.04 NPI Inc 2,081.67 4 of 22 OSR FY04 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY04 Expenditures Indirect Federal (continued) Nsabp Foundation 79,489.75 Oak Ridge Institute Scien 112,858.80 Ohio State U Res Foundation 46,833.40 Oregon Health Sciences 53,464.37 Other -592.29 Pacific Institute Research 66,712.55 Pan Lutheran Ministr 233,380.46 Pathfinder Internatl 161,514.78 Penn State University 18,961.53 Planned Parenthood 54,860.95 Policy Resrch Assoc 249,241.70 Princeton University 893,887.01 Rand Corporation,Inc 47,311.30 Research Foundation of Suny 785,165.57 Rhode Island Hospitl 564,197.50 Rice University 21,781.06 RTI 1,705,121.14 Rutgers 119,410.34 Salk Insitute 5,445.67 Science Appli Int'L 65,156.04 Scientific Sys Co 30,000.00 Scripps Research Institute 80,261.67 Seta Corporation 57,992.55 Shaw University 122,799.54 Sloan-Kettering Institute 78,489.20 Smithsonian Astrophy 11,392.79 Social & Scientific 1,386,077.16 Southcentral Foundation -0.27 Space Telescope Sci 12,384.85 Sprinkle Consulting 4,552.30 SRI International 197,741.80 St Louis University 400,561.57 State & Terr Injury 71,146.07 State of Alabama/Dph 37.58 Syracuse University 18,170.42 Tanglewood Research Inc 176,176.20 Texas A&M Research Foundation 1,443.62 The Noah Group, Llc -9,598.60 Thomas Jefferson Uni 41,222.73 Transanalytics 599.38 TRC Garrow Associate 9,476.67 Triangle Labs, Inc 182,760.66 Tulane University 92,776.20 University Calif- Lawrence Liver 57,822.23 University Corp Atmospheric R -32.62 University Med & Dentstry NJ 32,303.93 UNC-General Admin 62,272.08 Universidad Metropol 8,388.35 University Ala-Tuscaloosa 17,380.91 University Calif-Berkeley 144,068.61 University Calif-Davis 1,395.28 University Calif-Irvine 8,976.39 University Calif-San Franc 36,253.04 University Calif-Santa Cru 12.25 University Cincinnati -793.70 5 of 22 OSR FY04 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY04 Expenditures Indirect Federal (continued) University Colorado Health 63,215.11 University Conn Health Center 34,222.82 University Louisiana @ Laf 7,118.97 University Mass/Amherst 20,127.52 University Md Col Pk Foundation 17,643.72 University Md-Baltimore
Load more

Recommended publications
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Form 8-K Ligand Pharmaceuticals
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2020 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 (Address of principal executive offices) (Zip Code) (858) 550-7500 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • Milner Symposium 2020
    THERAPEUTICS SYMPOSIUM 2020 GLOBAL THERAPEUTIC ALLIANCE OVERVIEW A SERIES OF ONLINE EVENTS STARTING ON JUNE 12TH ALLIANCE GLOBAL THERAPEUTIC ALLIANCE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration. GLOBAL THERAPEUTIC ALLIANCE Research in the Milner Therapeutics Institute is funded by: Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p4), and the Alliance has been expanded with the Affiliated Company p8( ) and Affiliated Institutions scheme p37( ) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge. The Affiliated Venture Partnersprogramme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon. 3 CONSORTIUM ASTEX PHARMACEUTICALS MILNER THERAPEUTICS CONSORTIUM The Milner Therapeutics Astex is a leader in innovative drug discovery and Consortium is an academic- development, committed to the fight against cancer and industry partnership, active since diseases of the central nervous system. Astex is developing June 2015. This is underpinned a proprietary pipeline of novel therapies and has multiple
    [Show full text]
  • 4586728.98 in 2005
    Detail Awards by Sponsor Dept Name FY05 Award Federal National Cancer Institute 47,048,096.55 National Institute of Heart, Lung, and Blood 38,794,591.33 National Institute of General Medicine Science 30,400,147.18 National Institute of Child Health & Human Development 29,863,697.92 National Institute of Allergy & Infectious Diseases 27,492,973.12 National Science Foundation - Research 20,659,748.00 National Institute of Diabetes, Digestive & Kidney Diseases 19,575,845.00 National Center for Research Resources 19,179,710.00 National Institute of Mental Health-NIH 16,727,938.80 US Department of Education 15,868,100.00 US Agency for International Development 12,743,904.00 National Institute of Environmental Health Sciences 11,961,787.00 National Institute of Neurologic Disorders and Stroke 11,957,697.00 Centers for Disease Control 10,507,132.00 National Institute of Dental and Craniofacial Research 7,032,009.35 National Institute on Alcohol Abuse & Alcoholism 6,874,910.00 Bureau of Health Professions 5,797,479.00 National Institute of Arthritis Musculoskeletal Skin Disease 4,921,205.00 US Environmental Protection Agency - GRANTS 4,586,728.98 National Institute on Aging 4,159,889.94 National Institute on Drug Abuse 4,111,248.00 National Institute of Nursing Research 4,094,244.00 National Institute of Biomedical Imaging and Bioengineering 4,079,842.59 Maternal and Child Health Bureau 4,049,730.00 National Science Foundation - Training 3,877,378.00 National Center for Chronic Disease Prev & Health Promo(CDC) 3,384,180.00 US Department of Defense
    [Show full text]
  • An Insight Into Our Life Sciences and Healthcare Sector
    An insight into our Life Sciences and Healthcare Sector 2020 allenovery.com 2 An insight into our Life Sciences and Healthcare Sector | 2020 © Allen & Overy LLP 2020 3 Contents Introducing Allen & Overy 04 Full service, international support for the life sciences and healthcare sector 05 M&A/corporate finance 06 Licensing and collaborations 09 Patent litigation 11 Regulatory 13 Dispute resolution/arbitration 14 Equity and debt financing 15 Restructuring 16 Key contacts 17 allenovery.com 4 An insight into our Life Sciences and Healthcare Sector | 2020 Introducing Allen & Overy GEOGRAPHIC SPLIT BY TOTAL NUMBER OF LAWYERS† 141 Central & Eastern Europe 1,016 UK 929 Western Europe 440 129 Asia Pacific 185 Middle East North, Central & South America 77 Africa GLOBAL PRESENCE NORTH AMERICA EUROPE AFRICA ASIA PACIFIC New York Amsterdam Istanbul Casablanca Bangkok Seoul Washington, D.C. Antwerp London Johannesburg Beijing Shanghai Barcelona Luxembourg Hanoi Singapore CENTRAL & Belfast Madrid MIDDLE EAST Ho Chi Minh City Sydney SOUTH AMERICA Bratislava Milan Abu Dhabi Hong Kong Tokyo São Paulo Brussels Moscow Dubai Jakarta* Yangon Bucharest* Munich Perth * Associated office Budapest Paris ** Cooperation office Düsseldorf Prague † All figures represent the Frankfurt Rome financial year 2016/17 Hamburg Warsaw Source: Regional active headcount October 2018 KEY STATISTICS 5,400 2,300 550 40+ Number of staff Number of lawyers Number of partners Offices around the world © Allen & Overy LLP 2020 5 Full service, international support for the life sciences and healthcare sector Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.
    [Show full text]
  • Curriculum Vitae – Jac Wijkmans
    Curriculum Vitae – Jac Wijkmans Jac C.H.M. Wijkmans Jupiterweg 17, 5345 LR Oss +31 (0)6 2439 8484 [email protected] 10 January 1965, Roosendaal en Nispen Linkedin: http://nl.linkedin.com/pub/jac-wijkmans/11/a96/bb8 Work experience INNTREST Consultancy BV, Oss (2014–present) Owner/Senior Consultant Clients: ‒ uniQure Biopharma, Amsterdam: Global Development Project Leader a.i. leading the clinical development (Phase I/II) of gene therapy products for the treatment of the rare orphan neurodegenerative disorders Huntington’s disease and Sanfilippo B. Previously, ad interim project lead for hemophilia B gene therapy development. ‒ Center for Open Innovation in Lead Discovery (COILED), Nijmegen: Project leader, business developer and investor. In 2016, COILED was awarded a 4.4 M€ EFRO grant to valorize the breakthrough academic research of Spinoza laureate Prof. Mihai Netea (Radboudumc, Nijmegen). COILED partners are Radboud University Nijmegen, Radboudumc, Pivot Park Screening Centre, BioAxis Research, Inntrest and Pansynth. ‒ Kenniscentrum Plantenstoffen, Leiden: Business development/project management focused on developing new business concepts and revenue models for the Dutch horticulture sector. Initiatives are centered on the production of high-value plant components and their use in non- traditional markets such as pharmaceuticals, cosmetics, agrochemicals, fragrance and flavors. ‒ Radboud Universiteit, Nijmegen: Conducting feasibility study, drafting business plan and raising funds for new drug discovery center. This center presents a system innovation in pharmaceutical research in which a non-profit, open innovation drug discovery platform is provided to unlock and translate breakthrough academic research towards the development of drug candidates suited for clinical studies. ‒ PAO Farmacie, Zeist: Medicinal chemistry section post-graduate course ‘Quality Management’.
    [Show full text]
  • When Fragments Link : a Bibliometric Perspective on the Development of Fragment-Based Drug Discovery
    This is a repository copy of When fragments link : a bibliometric perspective on the development of fragment-based drug discovery. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132630/ Version: Accepted Version Article: Romasanta, Angelo K.S., van der Sijde, Peter, Hellsten, Iina et al. (4 more authors) (2018) When fragments link : a bibliometric perspective on the development of fragment-based drug discovery. Drug discovery today. ISSN 1359-6446 https://doi.org/10.1016/j.drudis.2018.05.004 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ When Fragments Link: A Bibliometric Perspective on the Development of Fragment-Based Drug Discovery Angelo K. S. Romasanta 1,2, Peter van der Sijde1, Iina Hellsten3, Roderick E. Hubbard4,5, Gyorgy M. Keseru6, Jacqueline van Muijlwijk-Koezen2 and Iwan J. P. de Esch2 1 Department of Science, Business & Innovation, Faculty of Science, VU University Amsterdam, De Boelelaan 1105, 1081 HV Amsterdam, The Netherland 2 Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands 3 Amsterdam School of Communication Research (ASCoR), University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, The Netherlands 4 Vernalis Research, Granta Park, Abington, Cambridge CB21 6GB, UK.
    [Show full text]
  • Vernalis Plc Annual Report and Accounts 2006 Contents
    V e r n a l Vernalis plc i s p l c Annual report and accounts 2006 A n n u a l r e p o r t a n d a c c o u n t s 2 0 0 6 Vernalis plc Annual report and accounts 2006 Contents 01 Who we are 02 Highlights 03 Chairman’s statement 04 Chief Executive’s review of operations 20 Financial review 24 Board of directors s 26 Report of the directors 29 Corporate governance 35 Remuneration report 42 Statement of directors’ t responsibilities s 43 Independent auditor’s report to the members of Vernalis plc 44 Consolidated income statement 45 Balance sheets 46 Statement of changes in c shareholders’ equity s 47 Cash flow statements 48 Notes to the financial statements 78 Shareholder information 80 Addresses and advisers e e e l r p p g s o o o r r e P P P Our employees are our Over the course of the 2007 potentially a most valuable asset as we year Vernalis has made transforming year for Vernalis work towards our goal of significant progress with the label expansion for improving patients’ lives in advancing its drug Frova ® into the short-term candidates, establishing its prevention of menstrual US commercial operations migraine as well as significant and relaunching Apokyn ® clinical news flow Vernalis plc Annual report and accounts 2006 01 Who we are Vernalis’ strategic goal is to become a sustainable, self-funding, R&D driven speciality bio-pharmaceutical company focused on the treatment of Central Nervous System (CNS) disorders.
    [Show full text]
  • Specialists in Cancer Drug Discovery & Development
    Specialists in Cancer Drug Discovery & Development Dr Tim Mitchell, CEO & Co-Founder Biotech Capital February 2016 Over half of us (adults under 65) Cancer drugs are expected to be 45% of anti-cancer NCE approvals will be diagnosed with cancer at the biggest selling therapeutic class 2001-2015 were kinase inhibitors some point in our lifetimes by 2017, with global sales ~$80Bn www.sareum.com Disclaimer The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA") for the purposes of Section 21 FSMA (Financial Promotion). Reliance on the information contained in this Presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment to which this Presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities. This document (“Presentation”), and the information contained in it, is being provided by Sareum Holdings plc (“the Company”) in connection with a Presentation to prospective investors being carried out by the Company which may or may not be in connection with a proposed placing of the Company’s shares (“Placing”). The contents of this Presentation are confidential. The information in this Presentation, which includes certain information drawn from public sources, does not purport to be comprehensive, and has not been independently verified and is liable to change. No assurance is given by the Company that any new ordinary shares in the Company will be issued.
    [Show full text]
  • Conference Handbook 2013
    genesis Conference Handbook 2013 2013 WELCOME TO EDINBURGH BIOQUARTER Designed to foster scientific creativity and encourage entrepreneurship among clinicians and researchers, BioQuarter combines world-class research from EDINBURGH LAUNCHES WORLD’S FIRST Edinburgh University’s College of Medicine and Veterinary Medicine with the long tradition of clinical VISUAL FIELD ANALYSER FOR CHILDREN excellence at NHS Lothian. Building one of Europe’s most In March 2012, Edinburgh significant concentrations of clinical and research assets, BioQuarter launched i2eye Diagnostics Limited, creators BioQuarter brings together a major teaching hospital, of the world’s first visual field medical school and three leading research institutes in analyser for children and hard- one location. Our seasoned business development team to-test patient groups. Based on research undertaken at the has spun out four new businesses and negotiated four University of Edinburgh and major industrial collaborations in less than two years, as NHS Lothian, this device enables well as generating 100 new product or business concepts young children’s field of vision to from its innovation competition. be tested accurately for the first the company has booked its first time, helping to pick up retinal orders and is set to take premises and optic nerve defects as well in our new incubator building, To find out more about how this commercialisation as certain forms of brain cancer. Nine the BioQuarter: partnership is building on Scotland’s successes Backed by private venture capital, www.i2eyediagnostics.com in life sciences, visit www.bioquarter.com Sponsors 3 Genesis 2013 Sponsors Contents Gold Sponsors Welcome 7 Keynote Speakers 8 - 9 Speaker Profiles 9 - 21 Programme 22-23 Floor Plan 24 Exhibitor List 25 Silver Sponsors The Genesis Talent Lounge 27 Exhibitor Profiles 31- 42 ON Hub 43 Corporate Patron Bronze Sponsors Corporate Sponsors Case Study Sponsors Partners Supporters Wifi Sponsor Media Partners Scotland.
    [Show full text]